Robert Uger, Chief Scientific Officer at Trillium Therapeutics Inc. (TRIL), sold 2,917 shares at $11.97 ($35K) on 2021-03-12, disclosed to the SEC on 2021-03-15.
Scheduled sale ($35k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRIL | SELL | 2021-05-11 | $34K | — | Filing → |
| TRIL | SELL | 2021-04-09 | $39K | — | Filing → |
| TRIL | SELL | 2021-03-10 | $37K | — | Filing → |